Medpace Q1 revenue beats analyst estimates

Medpace Holdings

22/04/2026 21:23

Overview

US clinical CRO's Q1 revenue rose 26.5% yr/yr, beating analyst expectations

GAAP net income and diluted EPS increased from prior year

Company forecasts 2026 revenue growth of up to 12.8% over 2025

Outlook

Medpace forecasts 2026 revenue between $2.755 bln and $2.855 bln

Company expects 2026 GAAP net income of $487 mln to $511 mln

Medpace sees 2026 diluted EPS between $16.68 and $17.50

Result Drivers

NEW BUSINESS AWARDS - Q1 net new business awards rose 23.7% yr/yr, supporting revenue growth

BACKLOG CONVERSION - Backlog conversion rate was 23.3%, contributing to higher revenue

Company press release: ID:nBw5jLgQYa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$706.6 mln
$697.66 mln (10 Analysts)
Q1 Net Income
$123.9 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Medpace Holdings Inc is $500.00, about 2.9% below its April 21 closing price of $514.90

The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 34 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)